Health TrialsbyHealthPanel

Urothelial Carcinoma of the Urinary Bladder

3

Review clinical trials related to Urothelial Carcinoma of the Urinary Bladder. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

This study is being conducted to evaluate the safety and tolerability of UGN-501 administered intravesically in adult participants with recurrent non-muscle invasive bladder cancer (NMIBC) and to determine the recommended Phase 2 dose (RP2D).

Participants needed: 30
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.Updated: Oct 13, 2026Locations: 15
Eligibility criteria

Participant must be 18 years of age or older at the time of signing informed con... [+27]

Current or previous evidence of muscle invasive, locally advanced nonresectable,... [+12]

Read more
Status: Recruiting

BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy

The objective of the study is to evaluate the efficacy and safety of T-bren in participants with HER2 expressing metastatic UC with progression on or after anti-PD-(L)1-based therapy.

Participants needed: 520
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: SystImmune Inc.Updated: Oct 13, 2026Locations: 2
Eligibility criteria

Histologically or cytologically documented metastatic or surgically unresectable... [+8]

Prior topoisomerase inhibitor-based ADC therapy. [+12]

Read more
Status: Recruiting

Bladder EpiCheck European Haematuria Study

The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed. Participants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.

Participants needed: 800
Trial details
Age: 45+Biological sex: AllType: ObservationalSponsor: Nucleix Ltd.Updated: Jan 22, 2026Locations: 5
Eligibility criteria

Participants aged 45 years or older [+4]

Participants with history of urothelial cancer in the bladder and/or upper urina... [+10]

Read more